



RECENT PUBLICATIONS BY THE
THORACIC ONCOLOGY RESEARCH GROUP

RECENT PUBLICATIONS BY THE THORACIC ONCOLOGY RESEARCH GROUP

- Elamin YY, Rafee S, Osman N, O Byrne KJ, Gately K. Thymidine Phosphorylase in Cancer; Enemy or Friend? *Cancer Microenviron.* 2015 Aug 23.
- Gately K, Forde L, Gray S, Morris D, Corvin A, Tewari P, O'Byrne K. Mutational analysis of the insulin like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. *Molecular and Clinical Oncology.* 2015;3: 1073-1079.
- O'Callaghan DS, Rexhepaj E, Gately K, Delaney D, O'Donnell D, Kay E, O'Connell F, Gallagher W and O'Byrne KJ. Tumor islet Foxp3+ T cell infiltration predicts poor outcome in non-small cell lung cancer. *ERJ.* 2015;(In Press).
- Stahel R, Bogaerts J, Ciardiello F, de Ruyscher D, Dubsy P, Ducreux M, Finn S, Laurent-Puig P, Peters S, Piccart M, Smit E, Sotiriou C, Tejpar S, Van Cutsem E, Tabernero J. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. *Cancer Treat Rev,* 41(2), 2015.
- Barr MP & O'Byrne KJ, Al-Sarraf N, Gray SG. VEGF-mediated cell survival in NSCLC: Implications for epigenetic targeting of VEGF receptors as a therapeutic approach. *Epigenomics* (In Press), 2015.
- Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne KJ. VEGF is an autocrine growth factor, signaling through Neuropilin-1 in non-small cell lung cancer. *Mol Cancer,* 14(1), 2015.
- Dowling P, Henry M, Paula Meleady, Clarke C, Gately K, O'Byrne K, Connolly E, Lynch V, Ballot J, Gullo G, Crown J, Moriarty M, Clynes M. Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden. *Metabolomics.* Aug 2014.
- Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med,* 371(23), 2014.
- Cuffe S, Hon H, Qiu X, Tobros K, Wong CK, De Souza B, McFarlane G, Masroor S, Azad AK, Hasani E, Rozanec N, Leighl N, Alibhai S, Xu W, Issa AM, Liu G. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. *Pharmacogenet Genomics,* 24(7), 2014.
- Azad AK, Qiu X, Boyd K, Kuang Q, Emami M, Perera N, Palepu P, Patel D, Chen Z, Cheng D, Feld R, Leighl NB, Shepherd FA, Tsao MS, Xu W, Liu G, Cuffe S. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). *Lung Cancer,* 84(3), 2014.
- Eng L, Su J, Qiu X, Palepu PR, Hon H, Fadhel E, Harland L, La Delfa A, Habbous S, Kashigar A, Cuffe S, Shepherd FA, Leighl NB, Pierre AF, Selby P, Goldstein DP, Xu W, Liu G. Second-hand smoke as a predictor of smoking cessation among lung cancer survivors. *J Clin Oncol,* 32(6), 2014.
- O'Brien CP, Taylor SE, O'Leary JJ, Finn SP. Molecular testing in oncology: problems, pitfalls and progress. *Lung Cancer,* 83(3), 2014.
- O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, Finn SP. Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns. *Mol Diagn Ther,* 18(1), 2014.
- Hayes BD, Finn SP. Kidney volume correlates with tumor diameter in renal cell carcinoma and is associated with histological poor prognostic features. *Int J Surg Pathol,* 22(1), 2014.
- Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Ludson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA. SPINK1 protein expression and prostate cancer progression. *Clin Cancer Res,* 20(18), 2014.
- Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprött K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. *PLoS One,* 9(7):e102112, 2014.
- d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. *PLoS One,* 9(6):e100816, 2014.
- Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. *Eur J Cancer,* 50(9), 2014.
- Nur MM, Finn S, Reynolds JV. Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells. *Expert Rev Anticancer Ther,* 14(3), 2014.
- Shikhrakab H, Elamin YY, O'Brien C, Gately K, Finn S, O'Byrne K, Osman N. Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience. *Ir Med J,* 107(7), 2014.
- Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn S, O'Byrne K, Gately K. Strategic targeting of the PI3K-NFkB axis in Cisplatin Resistant NSCLC. *Cancer Biol Ther,* 15(10), 2014.
- Dowling P, Pollard D, Larkin AM, Michael H, Meleady P, Gately K, O'Byrne K, Barr MP, Lynch V, Ballot J, Crown J, Moriarty M, O'Brien E, Morgan R, Clynes M. Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) found in tumour tissue and blood samples

- from patients diagnosed with lung cancer. *Mol BioSyst*, 11(3), 2014.
- Barr MP. Front Cover Image. *Biotechniques*, 56(4), 2014.
 - Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA. (2014). Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. *J Clin Oncol*, 32(25), 2014.
 - Barr M, Souan L, MacGabhann P, Müller J, Al Ashhab M, Jasser M, Hamza K, Al Hassoon S, Kuhn U, Infante D, Lawlor D, Gately K, Amireh E, O'Byrne K, Sughayer MA. The Establishment of an ISO Compliant Cancer Biobank for Jordan and its Neighboring Countries Through Knowledge Transfer and Training. *Biopreservation and Biobanking*. 12(1), 2014.
 - Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. *J Thorac Oncol*, 9(11), 2014.
 - Al-Alao BS, Gately K, et al. Prognostic impact of vascular and lymphovascular invasion in early lung cancer. *Asian Cardiovasc Thorac Ann*, 22(1), 2014.
 - Cathcart MC, Gately K, Cummins R, et al. Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. *Biochim Biophys Acta*, 1842(5), 2014.
 - Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, O'Byrne KJ. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. *Clin Lung Cancer*, 15(1), 2014.
 - Barr MP, Fennell DA, O'Leary JJ, Gray SG, O'Flaherty JD, Reynolds JV, O'Byrne KJ. The generation and characterisation of cisplatin resistant non-small cell lung cancer cell lines displaying stem-like features. *PLoS One*, 8(1), 2013.
 - Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I, Van Schaeybroeck S, Salto-Tellez M, Johnston PG, Fennell DA, Gately K, O'Byrne K, Cummins R, Kay E, Hamilton P, Stasik I, Longley DB. Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. *Cell Death Dis*, (4):e951, 2013.
 - Baird AM, O'Byrne KJ, Gray SG. (2013). Epigenetic regulation of chemokine/chemokine receptor expression. *Methods Mol Biol*, 1013, 2013.
 - Rani S, Gately K, O'Byrne K, O'Driscoll L. Global Analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. *Cancer Biol Ther*, 14(12), 2013.
 - Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M. RanGTPase: a candidate for Myc-mediated cancer progression. *J Natl Cancer Inst*, 105(7), 2013.
 - Al-Alao BS, O'Callaghan DS, Gately K, Nicholson S, Coate LE, O'Connell F, McGovern E, O'Byrne KJ, Young VK. Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre. *Ir J Med Sci*, 182(2), 2013.
 - Baird AM, Naicker K, Leonard J, Kilmartin L, O'Byrne KJ, Gray SG. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in Non-Small Cell Lung Cancer. *Lung Cancer*, 79(1), 2013.
 - Al-Alao BS, O'Callaghan DS, Gately K et al. Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre. *Ir J Med Sci*, 182(2), 2013.
 - Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O'Byrne KJ, Fennell D, Vacca AR, Nilsson S, Mutti L, Moro L. Estrogen Receptor activation impairs mitochondrial oxidative energy metabolism and tumor growth in vitro and in vivo. *Oncogenesis*, 2:e72, 2013.
 - Wright CM, Kirschner M, Cheng YY, O'Byrne KJ, Gray SG, Klebe S, McCaughan B, van Zandwijk N, Reid G. Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM). *PLoS One*, 8(8):e70940, 2013.
 - Versteyhe S, Klaproth B, Schjerling C, Jensen M, Palsgaard J, Gray SG, De Meyts P. IGF-I, IGF-II and insulin stimulate different gene expression responses through binding to the IGF-I receptor. *Front. Endocrinol*, 4(98), 2013.
 - Baird AM, Dockry E, Daly A, Stack E, O'Byrne KJ, Gray SG. IL-23R is epigenetically regulated and modulated by chemotherapy in Non-Small Cell Lung Cancer. *Front Oncol*, 3(162), 2013.
 - Gately K, Al-Alao B, Dhillon T, Mauri F, Cuffe S, Seckl M, O'Byrne K. Overexpression of the mammalian target of rapamycin (mTOR) and angiogenesis are poor prognostic factors in early stage NSCLC: a verification study. *Lung Cancer*, 75(2), 2012.
 - Paul I, Chacko AD, Stasik I, Busacca S, Crawford N, McCoy F, McTavish N, Wilson B, Barr M, O'Byrne KJ, Longley DB, Fennell DA. Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. *Cell Death Dis*, 3(449), 2012.
 - Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Fennell DA, Longley DB, Bueno R, Sugarbaker DJ, Broaddus VC. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. *PLoS One*, 7(12):e52753, 2012.
 - Gray SG, Baird AM, O'Kelly F, Nikolaidis G, Almgren M, Meunier A, Dockry E, Hollywood D, Ekstrom TJ, Perry AS, O'Byrne KJ. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. *Int J Mol Med*, 30(6), 2012.
 - Allott EH, Oliver E, Lysaght J, Gray SG, Reynolds JV, Roche HM, Pidgeon GP. The SGBS cell strain as a model for the in vitro study of obesity and cancer. *Clin Transl Oncol*, 14(10), 2012.

- Busacca S, Sheaff M, Gray SG, O'Byrne KJ, Soltermann A, Schmitt-Opitz I, Pass HI, Harkin P, Quinn JE, Fennell DA. BRCA1 is an essential mediator of vinorelbine induced apoptosis in mesothelioma. *J Pathol*, 227(2), 2012.
- Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM, Busacca S, Barbone D, Broaddus C, Gray SG, O'Byrne KJ, Johnston PG, Fennell DA, Longley DB. Histone Deacetylase Inhibitor induced apoptosis is FLIP/ caspase 8-dependent and HR23B-independent in malignant mesothelioma. *Eur J Cancer*, 48(7), 2012.
- Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. *J Pathol*, 224(4), 2011.
- Cathcart MC, Gray SG, Baird AM, Boyle E, Gately K, Kay E, Cummins R, Pidgeon GP, O'Byrne KJ. Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. *Cancer*, 117(22), 2011.
- Baird AM, Gray SG, O'Byrne KJ. IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. *Eur J Cancer*, 47(12), 2011.
- O'Byrne KJ, Baird AM, Kilmartin L, Leonard J, Sacevich C, Gray SG. Epigenetic Regulation of Glucose Transporters in Non-small Cell Lung Cancer. *Cancers*, 3(2), 2011.
- Baird AM, Gray SG, O'Byrne KJ. Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. *PLoS One*, 6(1), 2011.
- Cathcart MC, Gately K, Cummins R, Kay E, O'Byrne KJ, Pidgeon GP. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. *Mol Cancer*, 10(25), 2011.
- Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R; European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. *J Thorac Oncol*, 5(10), 2010.
- Versteyhe S, Blanquart C, Mahmood S, Christeff N, De Meyts P, Gray SG, Issad T. IRS-5 and -6 are poor substrates of the insulin receptor. *Molecular Medicine Reports*, 3(1), 2010.
- Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG, Longley DB. Pro-caspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. *Cell Death Differ*, 16(10), 2009.
- Gray SG, Al-Sarraf N, Baird AM, Cathcart MC, McGovern E, O'Byrne KJ. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. *Eur J Cancer*, 45(17), 2009.
- Gray SG, Al-Sarraf N, Baird AM, Cathcart MC, McGovern E, O'Byrne KJ. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. *Eur J Cancer*, 45(17), 2009.
- Kronic D, Moshir S, Greulich-Bode KM, Figueroa R, Cerezo A, Stammer H, Stark HJ, Gray SG, Nielsen KV, Hartschuh W, Boukamp P. (2009). Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss. *Biochim Biophys Acta*, 1792(4), 2009.
- Mahmood S, Borup R, Gray SG, De Meyts P. Gene expression profiling of human adipocyte responses to insulin and IGF-I signaling. *The Open Diabetes Journal*, 2, 2009.
- Field JK et al. EU-ELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. *Eur Respir J*, 34(6), 2009.
- Gray SG, Al-Sarraf N, Baird AM, Gately K, McGovern E, O'Byrne KJ. Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells. *Clin Lung Cancer*, 9(6), 2008.
- Al-Sarraf N, Gately K, Lucey J, Aziz R, Doddakula K, Wilson L, McGovern E, Young V. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. *Eur J Cardiothorac Surg*, 34(4), 2008.
- Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Mediastinal lymph node staging by means of positron emission tomography is less sensitive in elderly patients with non-small-cell lung cancer. *Clin Lung Cancer*, 9(1), 2008.
- Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E, Young V. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. *Eur J Cardiothorac Surg*, 33(1), 2008.
- Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. *Lung Cancer*, 60(1), 2008.
- Al-Sarraf N, Aziz R, Doddakula K, Gately K, Wilson L, McGovern E, Young V. Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography. *Interact Cardiovasc Thorac Surg*, 6(3), 2007.
- Doddakula K, Al-Sarraf N, Gately K, Hughes A, Tolan M, Young V, McGovern E. Predictors of acute renal failure requiring renal replacement therapy post cardiac surgery in patients with preoperatively normal renal function. *Interact Cardiovasc Thorac Surg*, 6(3), 2007.
- Al-Sarraf N, Mahmood S, Nørvig-Reiff J, Hinrichsen J, Teh BT, McGovern E, De Meyts P, O'Byrne KJ, Gray SG. DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. *Int J Cancer*, 121(5), 2007.
- Gray SG, Iglesias AH, Lizcano F, Villanueva R, Camelo S, Jingu H, Teh BT, Koibuchi N, Chin WW, Kokkotou E, Dangond F. Functional characterization of JMJD2A, a histone deacetylase and retinoblastoma-binding protein. *J Biol Chem*, 280(31), 2005.

REVIEWS & EDITORIALS

- MacDonagh L, Gray SG, Cuffe S, Finn SP, O'Byrne KJ, Barr MP. The Emerging Role of MicroRNAs in Resistance to Lung Cancer Treatments. *Cancer Treat Rev*, 41(2), 2015.
- O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP. The Role of DNA Repair Pathways in Cisplatin Resistant Lung Cancer. *Cancer Treat Rev*, 40(10), 2014.
- Gray SG. Epigenetic-based immune intervention for rheumatic diseases. *Epigenomics*, 6(2), 2014.
- Zhao J, Greene CM, Gray SG, Lawless MW. LncRNAs in liver cancer: what we know in 2014. *Expert Opin Ther Targets*, 18(10), 2014.
- Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. Targeting Nuclear Factor-kappa B to overcome resistance to chemotherapy. *Front Oncol*, 3(120), 2013.
- Gray SG. Perspectives on epigenetic based immune intervention for rheumatic diseases. *Arthritis Res Therapy*, 15(2), 2013.
- Barr MP, Mac Donagh L, O'Byrne KJ. Markers of response to platinum-based chemotherapy in lung cancer. *Lung Cancer Management*, 2(3), 2013.
- Heavey S, O'Byrne K, Gately K. Strategies for co-targeting the PI3K-AKT-mTOR pathway in NSCLC. *Cancer Treat Rev*, 40(3), 2013.
- Gao Y, Baird AM, Barr M, Gately K, O'Byrne KJ, Gray SG. Epigenetic therapy for cisplatin resistance in non-small cell lung cancer: the way forward? *Lung Cancer Management*, 2(1), 2013.
- O'Flaherty JD, Barr M, Fennell D, Richard D, Reynolds J, O'Leary J, O'Byrne K. The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. *J Thorac Oncol* 7(12), 2012.
- Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. *J Clin Pathol*, 65(1), 2012.
- O'Flaherty JD, Gray S, O'Leary JJ, Blackhall FH, O'Byrne KJ. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. *Lung Cancer* 76(1), 2012.
- O'Byrne KJ, Barr MP, Gray SG. The role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. *Cancers*, 3(1), 2011.
- Gray SG. Epigenetic treatment of neurological disease. *Epigenomics*, 3(4), 2011.
- Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. *Pigment Cell Melanoma Res*, 24(3), 2011.
- Gray SG. Targeting histone deacetylases for the treatment of Huntington's disease. *CNS Neurosci Ther*, 16(6), 2010.
- Lawless MW, O'Byrne KJ, Gray SG. Targeting oxidative stress in cancer. *Expert Opin Ther Targets*, 14(11), 2010.
- O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. *J Thorac Oncol*, 5(12), 2010.
- Lawless MW, Norris S, O'Byrne KJ, Gray SG. Oxidative Stress Induced Lung Cancer and COPD: Opportunities for Epigenetic Therapy. *J Cell Mol Med*, 13(9A), 2009.
- Gray SG, Crowe J, Lawless MW. Hemochromatosis: As a conformational disorder. *Int J Biochem Cell Biol*, 41(11), 2009.
- Lawless MW, Norris S, O'Byrne KJ, Gray SG. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones? *Curr Diabetes Rev*, 5(3), 2009.
- Lawless MW, Norris S, O'Byrne KJ, Gray SG. Histone Deacetylase inhibitors for the treatment of disease. *J Cell Mol Med*, 13(5), 2009.
- Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R. NF-kappa B Regulation: The Nuclear Response. *J Cell Mol Med*, 13(4), 2009.
- Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. *Endocr Metab Immune Disord Drug Targets*, 9(1), 2009.
- Gray SG, Fennell D, Mutti L, O'Byrne KJ. In arrayed ranks: array technology in the study of mesothelioma. *J Thorac Oncol*, 4(3), 2009.
- Lawless MW, Mankan AK, Gray SG, Norris S. Endoplasmic reticulum stress-A double edged sword for Z alpha-1 antitrypsin deficiency hepatotoxicity. *Int J Biochem Cell Biol*, 40(8), 2008.

BOOKS & BOOK CHAPTERS

- Gray SG. Epigenetic Cancer Therapy (1st Edition), 2015.
- Baird AM, O'Byrne KJ, Gray SG. ROS/RNS in epigenetic modifications in Systems biology of free radicals and anti-oxidants. Springer Verlag, 2014.
- Gately K. Lung Cancer: A Comprehensive Overview (Cancer Etiology, Diagnosis & Treatments Series). Nova Science Publishers Inc., 2013.
- Barr MP & O'Byrne KJ. Molecular Mechanisms of Cisplatin Resistance in Lung Cancer. In: Lung Cancer: A Comprehensive Overview. Nova Science Publishers, New York, 2013.
- Heavey S, O'Byrne K and Gately, K. Targeted Therapies in Non-Small Cell Lung Cancer. Chapter 7, In: Lung Cancer: A Comprehensive Review, Nova Publishers 2013.
- Baird AM, O'Byrne KJ, Gray SG. Epigenetic regulation of chemokine/chemokine receptor expression. In: Chemokine, Humana Press. Methods Mol Biol, 2013.
- Baird AM, Gray SG, O'Byrne KJ. Inflammation in lung carcinogenesis. In: Lung Cancer: A Comprehensive Overview, Nova Science Publishers Inc., 2013.
- Gray SG. The potential of epigenetic compounds in treating diabetes. Epigenetics in human disease. Academic Press, 2012.
- Lynam-Lennon N, Gray SG, Maher ST. MicroRNAs and human oncogenesis. In: Epigenetics in human disease. Academic Press, 2012.
- Gately K, Kerr K, O'Byrne K. Design, Construction, and Analysis of Cell Line Arrays and Tissue Microarrays for Gene Expression Analysis. Gene Expression Profiling 2nd Ed. Methods in Molecular Biology, Vol 784. Humana Press, 2011.
- Baird AM, O'Byrne KJ, Gray SG. ROS/RNS signaling in epigenetics. In: Systems biology of free radicals and anti-oxidants. Editor: I. Laher (UBC, Canada). Springer-Verlag, Berlin Heidelberg (Germany), Volume 1 (Chapter 20).
- Gray SG. Histone deacetylase inhibitors as a therapeutic modality in multiple sclerosis. Dr. Serena Guiducci & Dr Moncef Zouali Eds. Wiley Press, 2009.
- Peake MD, Entwistle J, Gray SG. Malignant pleural mesothelioma: clinical presentation, radiological evaluation and diagnosis. In: Malignant Pleural Mesothelioma. O'Byrne KJ and Rusch V Eds. Oxford University Press, 2006.
- Baird AM, Richard D, O'Byrne KJ, Gray SG. Epigenetics associated with lung cancer and mesothelioma in Epigenetics cancer therapy: from concepts to clinic. Springer Verlag.
- Perry AS, Baird AM, Gray SG. Epigenetics and celiac disease in Methods in Molecular Biology (Celiac disease). Springer Humana Press.

REPRESENTATION OF THORACIC ONCOLOGY RESEARCH, ST JAMES'S HOSPITAL AT NATIONAL & INTERNATIONAL CONFERENCES

- 2015 ASCO Annual Meeting, Chicago, USA (Posters)
- MMI (Molecular Medicine Ireland) Annual Scientific Meeting, 2015 (Poster)
- Stem Cells & Cancer Conference, Ventura, USA, 2015 (Poster)
- 13th Annual BTOG (British Thoracic Oncology Group) Conference, Dublin, 2015 (Posters & Orals)
- IACR (Irish Association for Cancer Research) Annual Meeting, Limerick, 2014 (Posters)
- 2014 ASCO Annual Meeting, Chicago, USA (Poster)
- 17th IMM (Institute of Molecular Medicine) Meeting, St James's Hospital, Dublin, 2014 (Posters)
- 9th International Cancer Conference (TCD), Dublin, 2014 (Posters)
- 12th Annual BTOG Conference, Dublin, 2014 (Posters)
- MMI Annual Scientific Meeting, 2014 (Posters & Oral)
- 15th World Conference on Lung Cancer, Sydney, 2013 (Posters & Orals)
- 3rd ESBB (European, Middle Eastern & African Society for Biopreservation & Biobanking) Annual Conference, Verona, 2013 (Posters)
- IACR Annual Conference, Dublin 2013 (Posters)
- 11th Annual BTOG Conference, Dublin, 2013 (Posters)
- 16th IMM Meeting, St James's Hospital, Dublin 2013 (Posters & Orals)
- MMI Annual Scientific Meeting, 2013 (Poster)
- European Society of Medical Oncology Annual Congress, Vienna, Austria, 2012 (Posters)
- 10th Annual BTOG Conference, Dublin, 2012 (Posters)
- 15th IMM Meeting, St James's Hospital, Dublin, 2012 (Posters)
- 14th World Conference on Lung Cancer, Amsterdam, 2011 (Oral & Posters)
- 9th Annual BTOG Conference, Dublin, 2011 (Posters)
- 14th IMM Meeting, St James's Hospital, Dublin 2011 (Posters)
- 8th Annual BTOG Conference, Dublin, 2010 (Posters)
- 13th IMM Meeting, St James's Hospital, Dublin 2010 (Posters)
- 1st AACR-IASLC (American Association for Cancer Research-International Association for the Study of Lung Cancer) International Conference on Molecular Origins of Lung Cancer, San Diego, USA, 2009 (Posters)
- 7th International Cancer Conference, Dublin, 2009 (Posters)
- 7th Annual BTOG Conference, Dublin, 2009 (Posters)
- 4th All-Ireland Cancer Conference, Dublin, 2008 (Posters)
- EACR-BACR (European Association for Cancer Research-British Association for Cancer Research) International Cancer Drug Discovery, Development & Evaluation Symposium, Nottingham, 2008 (Posters)
- 6th International Cancer Conference, Dublin, 2008 (Posters)
- IACR Annual Conference, Northern Ireland, 2008 (Posters)
- 12th World Conference on Lung Cancer, Korea, 2007 (Poster Presentations & Oral)
- IACR/Irish Society of Medical Oncology Annual Meeting, Ireland, 2007 (Oral)
- 6th Annual BTOG Conference, Dublin, 2007 (Posters)
- 3rd All Ireland Cancer Conference, Belfast, 2006 (Posters)
- 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, 2006 (Posters)
- IACR/Irish Society of Medical Oncology Annual Meeting, Ireland, 2006 (Posters)
- 11th World Conference on Lung Cancer, Barcelona, 2005 (Posters)
- Irish Association for Cancer Research AGM, Galway, 2014 (Posters & Oral)
- IMM Annual Meeting, St James's Hospital, Dublin, 2005 (Posters)
- Australian Lung Cancer Conference, Brisbane, 2014 (Poster & Oral)
- International Mesothelioma Interest Group Annual Meeting, Boston, USA, 2012 (Posters)

AWARDS & ACHIEVEMENTS

- Inflection Biosciences/TCD alliance (TORG) shortlisted for the Irish Pharma Awards 2015.
- Scholar-in-Training Award supported by Aflac, Inc. to support attendance at the AACR Special Conference on Targeting the PI3K-mTOR Network in Cancer (2014).
- Runner-up prize for Best Research Poster in Basic Science at the 12th Annual BTOG Meeting, Dublin (2014).
- ESMO Travel Award to attend Symposium on Signalling Pathways in Cancer: Targeting the PI3K/AKT/mTOR pathway (2014).
- European winners of GE Healthcare Image Of The Year Competition 2013.
- Award for Best Poster Presentation (Education & Standards) at the International ESBB Biobanking Conference, Verona (2013).
- Award for Best Poster at the IACR Annual Conference, Dublin (2013).
- Co-winners of the Roche GS Junior Sequencer Competition (2012).
- IASLC Fellowship Award (2011-2014)
- AACR/IASLC Scholar-In-Training Award (2010) for presentation of research at International Conference on Molecular Origins of Lung Cancer: Prospects for Personalised Prevention & Therapy, San Diego, USA (2009).
- Travel award for attendance at the 10th International Conference of the International Mesothelioma Interest Group (Kyoto, Japan), 2010.
- Overall Award for Best Research in Basic Science at 4th All-Ireland Cancer Conference (2008).
- Poster Prizes for Best Research in Basic Science at 7th Annual BTOG Meeting (2007, 2008, 2009).
- EACR Bursary Award (2008) to attend the Translational Cancer Research Summer School, University of Nottingham, United Kingdom (New Developments in Translational Cancer Research & International Symposium on Cancer Drug Discovery, Development & Evaluation).
- Recipient of Travel award from the St James Hospital Foundation to attend the EMBO Conference on chromatin and epigenetics (2007).
- Irish Cancer Society Oncology Scholars Awards (2006, 2007).
- Runner-up Poster Prize at 4th Annual BTOG Meeting (2006).
- HRB/NCI Education Awards (2006, 2007) for attendance at the Molecular Cancer Prevention NCI Summer Curriculum in Cancer Prevention, Maryland, USA.
- Awarded EACR Travel Fellowship (2005).
- European Haematology Association Travel Scholarships (2005).
- European Commission Marie-Curie Travel Scholarship for attendance and presentation of research at the European School of Haematology Conference on Angiogenesis, Cannes, France (2004).
- ICORG (All-Ireland Cooperative Oncology Research Group) Certifications in Good Clinical Practice (2004).



**ST. JAMES'S
HOSPITAL**
FOUNDATION
transforming patient care